<?xml version='1.0' encoding='utf-8'?>
<document id="32275771"><sentence text="The effects of weak and strong CYP3A induction by rifampicin on the pharmacokinetics of five progestins and ethinylestradiol compared to midazolam."><entity charOffset="50-60" id="DDI-PubMed.32275771.s1.e0" text="rifampicin" /><entity charOffset="93-103" id="DDI-PubMed.32275771.s1.e1" text="progestins" /><entity charOffset="108-124" id="DDI-PubMed.32275771.s1.e2" text="ethinylestradiol" /><entity charOffset="137-146" id="DDI-PubMed.32275771.s1.e3" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.32275771.s1.e0" e2="DDI-PubMed.32275771.s1.e0" /><pair ddi="false" e1="DDI-PubMed.32275771.s1.e0" e2="DDI-PubMed.32275771.s1.e1" /><pair ddi="false" e1="DDI-PubMed.32275771.s1.e0" e2="DDI-PubMed.32275771.s1.e2" /><pair ddi="false" e1="DDI-PubMed.32275771.s1.e0" e2="DDI-PubMed.32275771.s1.e3" /><pair ddi="false" e1="DDI-PubMed.32275771.s1.e1" e2="DDI-PubMed.32275771.s1.e1" /><pair ddi="false" e1="DDI-PubMed.32275771.s1.e1" e2="DDI-PubMed.32275771.s1.e2" /><pair ddi="false" e1="DDI-PubMed.32275771.s1.e1" e2="DDI-PubMed.32275771.s1.e3" /><pair ddi="false" e1="DDI-PubMed.32275771.s1.e2" e2="DDI-PubMed.32275771.s1.e2" /><pair ddi="false" e1="DDI-PubMed.32275771.s1.e2" e2="DDI-PubMed.32275771.s1.e3" /></sentence><sentence text="It is known that coadministration of CYP3A inducers may decrease the effectiveness of oral contraceptives containing progestins as mono-preparations or combined with ethinylestradiol"><entity charOffset="117-127" id="DDI-PubMed.32275771.s2.e0" text="progestins" /><entity charOffset="166-182" id="DDI-PubMed.32275771.s2.e1" text="ethinylestradiol" /><pair ddi="false" e1="DDI-PubMed.32275771.s2.e0" e2="DDI-PubMed.32275771.s2.e0" /><pair ddi="false" e1="DDI-PubMed.32275771.s2.e0" e2="DDI-PubMed.32275771.s2.e1" /></sentence><sentence text=" In a randomized clinical drug-drug interaction study, we investigated the effects of CYP3A induction on the pharmacokinetics of commonly used progestins and ethinylestradiol"><entity charOffset="158-174" id="DDI-PubMed.32275771.s3.e0" text="ethinylestradiol" /></sentence><sentence text=" Rifampicin was used to induce CYP3A"><entity charOffset="1-11" id="DDI-PubMed.32275771.s4.e0" text="Rifampicin" /></sentence><sentence text=" The progestins chosen as victim drugs were levonorgestrel, norethindrone, desogestrel, and dienogest as mono-products and drospirenone combined with ethinylestradiol"><entity charOffset="44-58" id="DDI-PubMed.32275771.s5.e0" text="levonorgestrel" /><entity charOffset="60-73" id="DDI-PubMed.32275771.s5.e1" text="norethindrone" /><entity charOffset="75-86" id="DDI-PubMed.32275771.s5.e2" text="desogestrel" /><entity charOffset="123-135" id="DDI-PubMed.32275771.s5.e3" text="drospirenone" /><entity charOffset="150-166" id="DDI-PubMed.32275771.s5.e4" text="ethinylestradiol" /><pair ddi="false" e1="DDI-PubMed.32275771.s5.e0" e2="DDI-PubMed.32275771.s5.e0" /><pair ddi="false" e1="DDI-PubMed.32275771.s5.e0" e2="DDI-PubMed.32275771.s5.e1" /><pair ddi="false" e1="DDI-PubMed.32275771.s5.e0" e2="DDI-PubMed.32275771.s5.e2" /><pair ddi="false" e1="DDI-PubMed.32275771.s5.e0" e2="DDI-PubMed.32275771.s5.e3" /><pair ddi="false" e1="DDI-PubMed.32275771.s5.e0" e2="DDI-PubMed.32275771.s5.e4" /><pair ddi="false" e1="DDI-PubMed.32275771.s5.e1" e2="DDI-PubMed.32275771.s5.e1" /><pair ddi="false" e1="DDI-PubMed.32275771.s5.e1" e2="DDI-PubMed.32275771.s5.e2" /><pair ddi="false" e1="DDI-PubMed.32275771.s5.e1" e2="DDI-PubMed.32275771.s5.e3" /><pair ddi="false" e1="DDI-PubMed.32275771.s5.e1" e2="DDI-PubMed.32275771.s5.e4" /><pair ddi="false" e1="DDI-PubMed.32275771.s5.e2" e2="DDI-PubMed.32275771.s5.e2" /><pair ddi="false" e1="DDI-PubMed.32275771.s5.e2" e2="DDI-PubMed.32275771.s5.e3" /><pair ddi="false" e1="DDI-PubMed.32275771.s5.e2" e2="DDI-PubMed.32275771.s5.e4" /><pair ddi="false" e1="DDI-PubMed.32275771.s5.e3" e2="DDI-PubMed.32275771.s5.e3" /><pair ddi="false" e1="DDI-PubMed.32275771.s5.e3" e2="DDI-PubMed.32275771.s5.e4" /></sentence><sentence text=" Postmenopausal women (n=12-14 per treatment group) received, in fixed sequence, a single dose of the victim drug plus midazolam without rifampicin, with rifampicin 10 mg/d (weak induction), and with rifampicin 600 mg/d (strong induction)"><entity charOffset="137-147" id="DDI-PubMed.32275771.s6.e0" text="rifampicin" /><entity charOffset="154-164" id="DDI-PubMed.32275771.s6.e1" text="rifampicin" /><entity charOffset="200-210" id="DDI-PubMed.32275771.s6.e2" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.32275771.s6.e0" e2="DDI-PubMed.32275771.s6.e0" /><pair ddi="false" e1="DDI-PubMed.32275771.s6.e0" e2="DDI-PubMed.32275771.s6.e1" /><pair ddi="false" e1="DDI-PubMed.32275771.s6.e0" e2="DDI-PubMed.32275771.s6.e2" /><pair ddi="false" e1="DDI-PubMed.32275771.s6.e1" e2="DDI-PubMed.32275771.s6.e1" /><pair ddi="false" e1="DDI-PubMed.32275771.s6.e1" e2="DDI-PubMed.32275771.s6.e2" /></sentence><sentence text=" The effects on progestin exposure were compared with the effects on midazolam exposure (as a benchmark)"><entity charOffset="16-25" id="DDI-PubMed.32275771.s7.e0" text="progestin" /><entity charOffset="69-78" id="DDI-PubMed.32275771.s7.e1" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.32275771.s7.e0" e2="DDI-PubMed.32275771.s7.e0" /><pair ddi="false" e1="DDI-PubMed.32275771.s7.e0" e2="DDI-PubMed.32275771.s7.e1" /></sentence><sentence text=" Unbound concentrations were evaluated for drugs binding to sex hormone binding globulin" /><sentence text=" Weak CYP3A induction, as confirmed by a mean decrease in midazolam exposure by 46%, resulted in minor changes in progestin exposure (mean decreases: 15-37%)"><entity charOffset="114-123" id="DDI-PubMed.32275771.s9.e0" text="progestin" /></sentence><sentence text=" Strong CYP3A induction, in contrast, resulted in mean decreases by 57-90% (mean decrease in midazolam exposure: 86%)" /><sentence text=" Namely, the magnitude of the observed induction effects varied from weak to strong" /><sentence text=" Our data might provide an impetus to revisit the currently applied clinical recommendations for oral contraceptives, especially for levonorgestrel and norethindrone containing products, and they might give an indication as to which progestin could be used, if requested, by women taking weak CYP3A inducers - although it is acknowledged that the exact exposure-response relationship for contraceptive efficacy is currently unclear for most progestins"><entity charOffset="133-147" id="DDI-PubMed.32275771.s12.e0" text="levonorgestrel" /><entity charOffset="152-165" id="DDI-PubMed.32275771.s12.e1" text="norethindrone" /><entity charOffset="233-242" id="DDI-PubMed.32275771.s12.e2" text="progestin" /><pair ddi="false" e1="DDI-PubMed.32275771.s12.e0" e2="DDI-PubMed.32275771.s12.e0" /><pair ddi="false" e1="DDI-PubMed.32275771.s12.e0" e2="DDI-PubMed.32275771.s12.e1" /><pair ddi="false" e1="DDI-PubMed.32275771.s12.e0" e2="DDI-PubMed.32275771.s12.e2" /><pair ddi="false" e1="DDI-PubMed.32275771.s12.e1" e2="DDI-PubMed.32275771.s12.e1" /><pair ddi="false" e1="DDI-PubMed.32275771.s12.e1" e2="DDI-PubMed.32275771.s12.e2" /></sentence><sentence text="" /></document>